Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 13/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345690 | 0.96 | MAPKAPK2 (0.54) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1343654 | 0.95 | MAPKAPK2 (0.52) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1343972 | 0.94 | MAPKAPK2 (0.56) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1343948 | 0.94 | MAPKAPK2 (0.56) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1346188 | 0.93 | MAPKAPK2 (0.52) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1345281 | 0.93 | MAPKAPK2 (0.52) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1345592 | 0.93 | MAPKAPK2 (0.52) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL4808641 | 0.93 | MAPKAPK2 (0.52) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1345648 | 0.92 | MAPKAPK2 (0.51) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B | |
| SCHEMBL1345413 | 0.92 | MAPKAPK2 (0.57) | MAPKAPK2MAPK1MAP2K1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063094-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-8063094-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-8063094-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-22 | — | — | US | disclosed |
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| WO-2008098096-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008098096-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053955-A1 | ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS | MAPKAPK2, IL2, MAP3K2 | MAPKAPK2 1/4885MAPK1 47/4885MAP2K1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.